While almost all PGx tests are performed to determine the dosage or the risk of side effects of treatments, APOE genotyping can also reveal an individual’s heritable AD risk, besides the risk of ARIA when treated with mAbs. This evidence concerns the gene APOE and Alzheimer disease.